E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Treatment of acute angioedema attacks in patients with hereditary angioedema (HAE). |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10019860 |
E.1.2 | Term | Hereditary angioedema |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To confirm efficacy and safety of rhC1INH at a dose of 50 U/kg when used for the treatment of acute angioedema attacks in patients with HAE.
|
|
E.2.2 | Secondary objectives of the trial |
- To estimate the minimal important difference (MID) of the visual analogue scale (VAS) score used in the assessment of patient-reported outcomes during an acute attack of angioedema in patients with HAE. - To assess efficacy, safety and immunogenicity of rhC1INH when used for the repeat treatment of acute angioedema attacks in patients with HAE.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion Criteria at Screening: 1. Aged at least 18 years 2. Signed written informed consent 3. Clear clinical and laboratory diagnosis of HAE with baseline plasma level of functional C1INH of less than 50% of normal 4. Willingness and ability to comply with all protocol procedures
Inclusion Criteria for randomized treatment: 1. Above screening criteria continue to be met 2. Clinical symptoms of HAE attack 3. Onset of symptoms less than 5 hours before the time at which medical evaluation determined eligibility for inclusion 4. ‘Overall severity VAS’ score for at least one anatomical location at the time of initial evaluation and Time 0 of at least 50 mm 5. No evidence of regression of angioedema symptoms scored with VAS at t = 0 h compared with VAS score at the time of initial evaluation, i.e. no decrease in symptoms of angioedema scored with overall VAS at t = 0 h compared with score at the time of initial evaluation by 20 mm or more at any eligible site.
Inclusion Criteria for Open Label Treatment: 1. Above screening and randomization criteria continue to be met for subsequent eligible attack. 2. 24 hours have passed since the patient’s randomized or last open-label treatment. |
|
E.4 | Principal exclusion criteria |
Exclusion Criteria at Screening: Medical history of allergy to rabbits or rabbit-derived products (including rhC1INH), or positive anti-rabbit dander IgE test (cut off >0.35 kU/L; ImmunoCap® assay; Phadia or equivalent). 1. A diagnosis of acquired C1INH deficiency (AAE) 2. Pregnancy, or breastfeeding, or current intention to become pregnant 3. Treatment with any investigational drug in the past 30 days 4. Any clinically significant abnormality in the routine hematology and biochemistry that, in the opinion of the investigator, might interfere with the evaluation of study objectives 5. Any condition or treatment that, in the opinion of the investigator, might interfere with the evaluation of study objectives
Exclusion Criteria for randomized treatment: 1. Any changes since screening that would exclude patient based on above exclusion criteria 2. Positive pregnancy test (urine or serum).
Exclusion Criteria for Open Label Treatment: 1. Any changes since screening that would exclude subject based on above exclusion criteria. 2. Positive pregnancy test (urine or serum). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Primary efficacy variable: Time to beginning of relief, defined as the time between baseline (beginning of treatment administration) and the first time point at which the ‘overall severity VAS’ decreases by at least the MID at any eligible location, with persistence of the decrease at the next assessment time so that for the next value at the location a decrease of at least the MID with respect to baseline is also observed. Sensitivity analyses of the time to beginning of relief will be performed using the other two estimates of the MID above and using a decrease of 20mm or greater, as defined in previous studies with rhC1INH. - Time to minimal symptoms defined as the time between baseline (beginning of treatment administration) and the first time point at which the ‘overall severity VAS’ decreases to a value less than the MID (as identified in the above estimates and for 20 mm), at all locations.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
with an open-label extension phase |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 5 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study will end after 50 patients receive randomized treatment and the Sponsor determines sufficient data have been collected on repeat treatments in the OLE phase. The end of the study is defined as the last patient’s last visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 12 |
E.8.9.2 | In all countries concerned by the trial days | 0 |